Drug Development for Chronic Cancers: Time to Think Differently?
Mené sur 829 patientes atteintes d'un cancer de l’ovaire, de la trompe de Fallope ou du péritoine réfractaire à une chimiothérapie à base de sels de platine, cet essai de phase III compare , du point de vue de la survie globale, le patupilone et la doxorubicine lyposomale pégylée
As the treatments for epithelial cancers have inched forward, the chronic management of patients with high performance status has become a common problem in the practice of oncology. This conundrum is clearly illustrated by the excellent, yet negative, randomized trial by Colombo et al1 that accompanies this editorial. This large, well-designed clinical trial tested another modestly active agent, patupilone, in comparison with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer. Sadly, this study did not meet its prespecified superiority end point, namely an overall survival improvement compared with the use of PLD...
Journal of Clinical Oncology , éditorial en libre accès, 2012